Cargando…

Frequency of infections in 948 MPN patients: a prospective multicenter patient-reported pilot study

Detalles Bibliográficos
Autores principales:	Crodel, Carl C., Jentsch-Ullrich, Kathleen, Koschmieder, Steffen, Kämpfe, Dietrich, Griesshammer, Martin, Döhner, Konstanze, Jost, Philipp J., Wolleschak, Denise, Isfort, Susanne, Stegelmann, Frank, Jilg, Stefanie, Hofmann, Verena, Auteri, Guiseppe, Rachow, Tobias, Ernst, Philipp, Brioli, Annamaria, von Lilienfeld-Toal, Marie, Hochhaus, Andreas, Palandri, Francesca, Heidel, Florian H.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2020
Materias:	Letter
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7261209/ https://www.ncbi.nlm.nih.gov/pubmed/32474573 http://dx.doi.org/10.1038/s41375-020-0890-1

Ejemplares similares

Clinicohematologic and molecular response of essential thrombocythemia patients treated with pegylated interferon-α: a multi-center study of the German Study Group-Myeloproliferative Neoplasms (GSG-MPN)
por: Stegelmann, Frank, et al.
Publicado: (2023)

Efficacy and safety of ruxolitinib in patients with newly-diagnosed polycythemia vera: futility analysis of the RuxoBEAT clinical trial of the GSG-MPN study group
por: Koschmieder, Steffen, et al.
Publicado: (2022)

Challenges of patients with myeloproliferative neoplasms (MPN) in times of COVID: First results from a patient survey by the German Study Group for MPN
por: Kricheldorf, Kim, et al.
Publicado: (2021)

Significant association of cutaneous adverse events with hydroxyurea: results from a prospective non-interventional study in BCR-ABL1-negative myeloproliferative neoplasms (MPN) - on behalf of the German Study Group-MPN
por: Stegelmann, Frank, et al.
Publicado: (2020)

Publisher Correction: Significant association of cutaneous adverse events with hydroxyurea: results from a prospective non-interventional study in BCR-ABL1-negative myeloproliferative neoplasms (MPN) - on behalf of the German Study Group-MPN
por: Stegelmann, Frank, et al.
Publicado: (2021)

Kidney Dysfunction Is Associated with Thrombosis and Disease Severity in Myeloproliferative Neoplasms: Implications from the German Study Group for MPN Bioregistry
por: Gecht, Judith, et al.
Publicado: (2021)

Diagnosis and treatment of MPN in real life: exploratory and retrospective chart review including 960 MPN patients diagnosed with ET or MF in Germany
por: Schmidt, Andreas, et al.
Publicado: (2023)

P1055: CLINICAL AND GENETIC RESULTS OF THE PHASE IB/II TRIAL MPNSG-0212: RUXOLITINIB PLUS POMALIDOMIDE IN MYELOFIBROSIS WITH ANEMIA
por: Stegelmann, F., et al.
Publicado: (2022)

Bleeding, thrombosis, and anticoagulation in myeloproliferative neoplasms (MPN): analysis from the German SAL-MPN-registry
por: Kaifie, A., et al.
Publicado: (2016)

Holding CoVID in check through JAK? The MPN-approved compound ruxolitinib as a potential strategy to treat SARS-CoV-2 induced systemic hyperinflammation
por: Heidel, F., et al.
Publicado: (2020)

Validation of myeloproliferative neoplasms associated risk factor RDW as predictor of thromboembolic complications in healthy individuals: analysis on 6849 participants of the SHIP-study
por: Manz, Kirsi, et al.
Publicado: (2023)

Case report: false positive elevated serum‐galactomannan levels after autologous hematopoietic stem cell transplantation caused by oral nutritional supplements
por: Rachow, Tobias, et al.
Publicado: (2016)

MPN patients harbor recurrent truncating mutations in transcription factor NF-E2
por: Jutzi, Jonas S., et al.
Publicado: (2013)

Pomalidomide combinations are a safe and effective option after daratumumab failure
por: Brioli, Annamaria, et al.
Publicado: (2023)

P960: EXTRAMEDULLARY MYELOMA REMAINS AN UNMET CLINICAL NEED EVEN IN THE ERA OF NOVEL AGENT. ANALYSIS OF THE SINGLE CENTER MCOHORT.
por: Brioli, Annamaria, et al.
Publicado: (2023)

Outcome of 129 Pregnancies in Polycythemia Vera Patients: A Report of the European LeukemiaNET
por: Wille, Kai, et al.
Publicado: (2023)

Progression of Myeloproliferative Neoplasms (MPN): Diagnostic and Therapeutic Perspectives
por: Baumeister, Julian, et al.
Publicado: (2021)

Breakthrough infections in MPN-COVID vaccinated patients
por: Barbui, Tiziano, et al.
Publicado: (2022)

Cytoreductive treatment in real life: a chart review analysis on 1440 patients with polycythemia vera
por: Crodel, Carl C., et al.
Publicado: (2021)

Longer-term response to SARS-CoV-2 vaccine in MPN patients: Role of ruxolitinib and disease severity
por: Auteri, Giuseppe, et al.
Publicado: (2022)

Second Versus First Wave of COVID-19 in Patients with MPN
por: Barbui, Tiziano, et al.
Publicado: (2021)

Protection Against Breakthrough Delta/Omicron Variants in Vaccinated Patients with Myeloproliferative Neoplasms (MPN)
por: Barbui, Tiziano, et al.
Publicado: (2022)

P1009: PREDICTORS OF HOSPITALIZATION AND SEVERE OUTCOMES IN PATIENTS WITH MPN AND COVID-19
por: Barbui, T., et al.
Publicado: (2022)

Proliferative activity is disturbed in myeloproliferative neoplasms (MPN), myelodysplastic syndrome (MDS), and MDS/MPN diseases. Differences between MDS and MDS/MPN
por: Mestrum, Stefan G. C., et al.
Publicado: (2020)

P948: REAL-WORLD EVIDENCE OF BISPHOSPHONATES FOR MULTIPLE MYELOMA
por: Muñoz, Maria Nieves Lopez, et al.
Publicado: (2023)

Rapid induction of complete molecular remission by sequential therapy with LDAC and sorafenib in FLT3-ITD-positive patients unfit for intensive treatment: two cases and review of the literature
por: Wolleschak, Denise, et al.
Publicado: (2013)

Determinants of Covid19 disease and of survival after Covid19 in MPN patients treated with ruxolitinib
por: Palandri, Francesca, et al.
Publicado: (2023)

P1011: PREDICTORS OF COVID-19 DISEASE AND SURVIVAL TO COVID-19 IN MPN PATIENTS TREATED WITH RUXOLITINIB
por: Palandri, F., et al.
Publicado: (2022)

PB2187: ARTERIAL AND VENOUS THROMBOEMBOLIC COMPLICATIONS IN 832 PATIENTS WITH BCR-ABL-NEGATIVE MYELOPROLIFERATIVE NEOPLASMS (MPN)
por: Wille, Kai, et al.
Publicado: (2023)

Second versus first wave of COVID-19 in patients with MPN
por: Barbui, Tiziano, et al.
Publicado: (2022)

Clinical and sonographic improvement of developmental dysplasia of the hip: analysis of 948 patients
por: Bakti, Karim, et al.
Publicado: (2022)

The Unfolded Protein Response Is a Major Driver of LCN2 Expression in BCR–ABL- and JAK2V617F-Positive MPN
por: Tillmann, Stefan, et al.
Publicado: (2021)

Long-term follow-up of recovered MPN patients with COVID-19
por: Barbui, Tiziano, et al.
Publicado: (2021)

948. The Changing Dynamics of Hospitalizations Among People Living with HIV Over Time
por: Gujaran, Shruti, et al.
Publicado: (2020)

Alcohol intake and bradyarrhythmia risk: a cohort study of 407 948 individuals( )
por: Tu, Samuel J, et al.
Publicado: (2022)

Influenza virus infections in patients with malignancies –– characteristics and outcome of the season 2014/15. A survey conducted by the Infectious Diseases Working Party (AGIHO) of the German Society of Haematology and Medical Oncology (DGHO)
por: Hermann, B., et al.
Publicado: (2016)

NK Cells in Myeloproliferative Neoplasms (MPN)
por: Naismith, Erin, et al.
Publicado: (2021)

Impact of COVID19 Pandemic on an International MPN Patient Population: Survey Results from 1560 MPN Patients
por: Palmer, Jeanne M., et al.
Publicado: (2020)

Detection of community‐acquired respiratory viruses in allogeneic stem‐cell transplant recipients and controls—A prospective cohort study
por: Rachow, Tobias, et al.
Publicado: (2020)

CALR frameshift mutations in MPN patient-derived iPSCs accelerate maturation of megakaryocytes
por: Olschok, Kathrin, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_pkttfp5tu9onc0gfjakauksvj7